{"filing":{"accession_number":"0001437749-26-021309","cik":"0001053691","ticker":"CRVO","company_name":"CervoMed Inc.","form":"8-K","filing_date":"2026-06-22","report_date":null,"primary_document":"crvo20260622_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1053691/000143774926021309/crvo20260622_8k.htm"},"events":[{"id":12764,"run_id":11323,"accession_number":"0001437749-26-021309","anchor_item_number":"8.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"CervoMed closed a registered direct offering of 2,500,000 shares of common stock at $4.00 per share, raising $10 million in gross proceeds pursuant to an effective Form S-3 shelf registration statement. This registered equity issuance dilutes existing shareholders and is material given the company's disclosed going-concern risks and dependence on additional financing to advance its Phase 3 trial.","company_name":"CervoMed Inc.","ticker":"CRVO","filing_date":"2026-06-22","form":"8-K","submitted_at":null,"items":[{"id":9710,"accession_number":"0001437749-26-021309","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"CervoMed announced the closing of a registered direct offering of 2,500,000 shares at $4.00 per share, generating $10 million in gross proceeds. This is a registered equity issuance under a Form S-3 shelf registration, which dilutes existing shareholders. The materiality is underscored by the company's disclosed going-concern risks and dependence on additional financing to advance its Phase 3 trial, making this capital raise material to investors assessing the registrant's financial position and runway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T20:51:01.398850+00:00","company_name":"","ticker":null,"filing_date":""},{"id":9711,"accession_number":"0001437749-26-021309","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"CervoMed closed a registered direct offering of 2,500,000 shares of common stock at $4.00 per share, raising $10 million in gross proceeds. This is a registered equity issuance that dilutes existing shareholders. The filing explicitly states the offering was made pursuant to an effective Form S-3 shelf registration statement, and the press release confirms the closing on June 22, 2026. While registered (not unregistered), this is a material capital-raising event typical of clinical-stage biotech companies and would materially affect investor assessment of ownership dilution and the company's financing strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T20:51:01.398850+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":9710,"accession_number":"0001437749-26-021309","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"CervoMed announced the closing of a registered direct offering of 2,500,000 shares at $4.00 per share, generating $10 million in gross proceeds. This is a registered equity issuance under a Form S-3 shelf registration, which dilutes existing shareholders. The materiality is underscored by the company's disclosed going-concern risks and dependence on additional financing to advance its Phase 3 trial, making this capital raise material to investors assessing the registrant's financial position and runway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T20:51:01.398850+00:00","company_name":"CervoMed Inc.","ticker":"CRVO","filing_date":"2026-06-22"},{"id":9711,"accession_number":"0001437749-26-021309","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"CervoMed closed a registered direct offering of 2,500,000 shares of common stock at $4.00 per share, raising $10 million in gross proceeds. This is a registered equity issuance that dilutes existing shareholders. The filing explicitly states the offering was made pursuant to an effective Form S-3 shelf registration statement, and the press release confirms the closing on June 22, 2026. While registered (not unregistered), this is a material capital-raising event typical of clinical-stage biotech companies and would materially affect investor assessment of ownership dilution and the company's financing strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T20:51:01.398850+00:00","company_name":"CervoMed Inc.","ticker":"CRVO","filing_date":"2026-06-22"}]}